Dyne Therapeutics, Inc. (NASDAQ:DYN) Stake Raised by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. boosted its holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN) by 2.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 667,452 shares of the company’s stock after acquiring an additional 18,800 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Dyne Therapeutics were worth $15,725,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. FMR LLC raised its holdings in Dyne Therapeutics by 69.7% during the 3rd quarter. FMR LLC now owns 9,026,697 shares of the company’s stock worth $324,239,000 after buying an additional 3,707,734 shares during the period. RTW Investments LP grew its stake in Dyne Therapeutics by 6.8% during the 3rd quarter. RTW Investments LP now owns 6,818,641 shares of the company’s stock valued at $244,926,000 after acquiring an additional 431,503 shares in the last quarter. Janus Henderson Group PLC grew its stake in Dyne Therapeutics by 47.3% during the 3rd quarter. Janus Henderson Group PLC now owns 6,813,163 shares of the company’s stock valued at $244,755,000 after acquiring an additional 2,189,339 shares in the last quarter. RA Capital Management L.P. grew its stake in Dyne Therapeutics by 5.5% during the 3rd quarter. RA Capital Management L.P. now owns 6,381,144 shares of the company’s stock valued at $229,211,000 after acquiring an additional 331,940 shares in the last quarter. Finally, State Street Corp grew its stake in Dyne Therapeutics by 13.8% during the 3rd quarter. State Street Corp now owns 3,641,859 shares of the company’s stock valued at $130,816,000 after acquiring an additional 440,890 shares in the last quarter. Institutional investors and hedge funds own 96.68% of the company’s stock.

Insiders Place Their Bets

In other news, insider Oxana Beskrovnaya sold 2,598 shares of the company’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $13.95, for a total transaction of $36,242.10. Following the completion of the transaction, the insider now directly owns 199,087 shares in the company, valued at $2,777,263.65. The trade was a 1.29 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold 6,237 shares of company stock valued at $77,760 over the last 90 days. 20.77% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

DYN has been the topic of several research analyst reports. Guggenheim reaffirmed a “buy” rating on shares of Dyne Therapeutics in a research note on Friday, January 24th. Piper Sandler lowered their target price on Dyne Therapeutics from $53.00 to $48.00 and set an “overweight” rating on the stock in a research note on Friday, February 28th. HC Wainwright reaffirmed a “buy” rating and set a $46.00 target price on shares of Dyne Therapeutics in a research note on Monday. BMO Capital Markets initiated coverage on Dyne Therapeutics in a research note on Wednesday, March 12th. They set an “outperform” rating and a $50.00 target price on the stock. Finally, Chardan Capital reaffirmed a “buy” rating and set a $50.00 target price on shares of Dyne Therapeutics in a research note on Monday. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, twelve have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Dyne Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $48.85.

Dyne Therapeutics Stock Down 1.1 %

Shares of Dyne Therapeutics stock opened at $12.26 on Friday. The stock has a market capitalization of $1.39 billion, a P/E ratio of -3.44 and a beta of 1.11. The stock has a 50 day moving average price of $13.68 and a two-hundred day moving average price of $24.49. Dyne Therapeutics, Inc. has a 12-month low of $11.18 and a 12-month high of $47.45.

Dyne Therapeutics (NASDAQ:DYN) last announced its earnings results on Tuesday, March 4th. The company reported ($0.88) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.04. Sell-side analysts anticipate that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current year.

Dyne Therapeutics Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.